Skip to main content
logo
Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.180
-0.050 (-2.24%)
At close: Sep 29, 2026, 4:00 PM EDT
2.180
0.00 (0.00%)
After-hours: Sep 29, 2026, 8:00 PM EDT

Can-Fite BioPharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.410.410.670.740.810.85
Revenue Growth
0%-39.91%-9.29%-8.27%-5.04%11.80%
Gross Profit
0.410.410.670.740.810.85
Operating Income
-9.73-9.95-8.13-8.2-10.1-12.84
Net Income
-9.55-9.83-7.88-7.63-10.17-15.21
Earnings Per Share
-3.26-5.97-10.86-17.92-37.41-82.48
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
7.048.547.898.927.9919.14
Total Debt
0.050.070.10.040.060.12
Net Cash (Debt)
6.998.477.788.887.9319.02
Net Cash Growth
-17.42%8.81%-12.37%12.08%-58.32%129.76%
Net Cash Per Share
2.385.1410.7320.8429.15103.14

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-9.51-8.95-7.64-8.44-10.8-9.86
Capital Expenditures
-0-0-0.01-0-0.01-0.01
Free Cash Flow
-9.51-8.95-7.64-8.44-10.81-9.87
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-2402.96%-2456.79%-1206.23%-1102.96%-1246.42%-1505.51%
Pretax Margin
-2358.77%-2426.67%-1169.14%-1027.46%-1255.93%-1478.90%
Profit Margin
-2358.76%-2426.67%-1169.14%-1027.46%-1255.93%-1782.53%
FCF Margin
-2348.89%-2210.12%-1133.83%-1136.20%-1334.57%-1156.98%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
11.7260.8423.0911.9024.0645.20